clairop

How Often Do You Need a Colonoscopy With Crohn's?

There is no single schedule. Crohn's colonoscopies follow four different clocks: cancer surveillance, treatment checks, post-surgery checks and symptoms.

Clairop Team25 min read

Photo: Romain Gal / Unsplash

The short answer

There is no one interval, because Crohn's colonoscopies answer four different questions. Cancer surveillance starts about 8 years after symptoms begin when the colon is involved, then repeats every 1, 3 or 10 years depending on risk. Treatment checks and post-surgery checks are tied to events, such as a therapy change or an ileocolic resection, not to a calendar.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

A colonoscopy is a camera test that lets a doctor look at the lining of the colon and the end of the small intestine. If you have Crohn's disease, there is no single answer to how often you need a colonoscopy, because the scope is being used to answer four different questions. One is about cancer risk and is driven by how long you have had disease and where it sits. One is about whether a treatment is working. One is about the join in your bowel after surgery. And one is about a change in how you feel. Each has its own clock, and most of the confusion online comes from mixing them up. Why scheduled monitoring matters even in quiet years is explained in can Crohn's disease stay mild long term.

This guide separates the clocks, quotes the numbers from the guidelines we opened for this article, and says plainly where a number is missing or where documents disagree. It will not tell you your interval, because that depends on your own history and only your gastroenterologist has it. It should leave you able to ask a sharper question at your next appointment.

How often do you need a colonoscopy with Crohn's disease?

The honest short answer is "when your team needs the information the scope gives". For cancer surveillance, the first colonoscopy is suggested about 8 years after your symptoms started if Crohn's affects the colon, and the repeat interval then depends on risk factors. For a treatment check, it is usually after the drug has had enough time to work, or before a switch. After bowel surgery it is typically at about 6 to 12 months. For new or worsening symptoms it is whenever your doctor needs to look.

Here is the whole picture in one table. Numbers come from the sources we opened, linked in the sections below.

Reason for the scopeWho it applies toTypical timing in the guidance we readMain source
Cancer surveillance, baselineCrohn's affecting the colonAbout 8 years after symptom onset; from diagnosis if primary sclerosing cholangitis (PSC)BSG 2025, ECCO 2023
Cancer surveillance, repeatAs above, set by riskAnnual (higher risk), every 3 years (intermediate), 10-year reassessment (no extra risk factors) in BSG 2025; 1, 2 to 3 or 5 years in ECCO 2023BSG 2025, ECCO 2023
Treat-to-target checkActive disease, new or changed therapyResponse evaluated within 6 months of starting therapy; also considered before a switchECCO-ESGAR 2019, STRIDE-II
Post-surgery checkAfter ileocolonic resectionIleocolonoscopy around 6 months (BSG); within 6 to 12 months (ECCO-ESGAR)BSG 2019, ECCO-ESGAR 2019
Symptom or complication work-upNew symptoms, relapse, persistent activityWhen clinically neededECCO-ESGAR 2019
Cancer surveillanceCrohn's only in the small bowel, or colon beyond rectum not involvedNot offered; general population screening insteadBSG 2025

Two things worth noticing straight away. First, the same person can be in more than one row at once. Someone with colonic Crohn's who has just switched biologics is on a surveillance clock and a treatment clock. Second, only one row involves a calendar anchored to the date your symptoms started. The rest are triggered by something happening.

What people with Crohn's say about their own schedules

"How often do you get one?" is a perennial question in r/CrohnsDisease, and the answers vary widely. In a thread asking how often people have colonoscopies, people reported anything from every few years to yearly, and several said their interval depended on whether they were flaring or in remission, how long they had had Crohn's, and other complications. A similar thread from people in remission shows the same spread, with some mentioning alternating scopes with scans, and others noting that practice seemed to differ between countries. That spread is exactly why the clocks above matter: your interval is set by your own situation and your team, not by what another person was told.

Clock one: how often is colon cancer surveillance needed?

Surveillance colonoscopy looks for dysplasia, the pre-cancerous change that can develop in a colon with long-standing inflammation. It is a different job from checking whether your Crohn's is active, and it is driven by risk, not by how you feel.

Why Crohn's raises colon cancer risk, and when it does not

Risk is not spread evenly across Crohn's. A meta-analysis found the relative risk of colorectal cancer in Crohn's overall was 2.5 (95% CI 1.3 to 4.7), but 4.5 (1.3 to 14.9) in people with colonic disease and 1.1 (0.8 to 1.5) in ileal disease, close to no increase (Canavan 2006). The authors estimated a cumulative risk of 2.9% at 10 years and said the value of screening needed rigorous appraisal. The European guideline states the same point plainly: an increased risk of colorectal cancer is only present in Crohn's patients with colonic involvement (Gordon 2023).

The 2025 BSG guideline backs this up. It gives isolated terminal ileal Crohn's a hazard ratio of 1.09 (0.89 to 1.34), described as low risk, and suggests that people whose Crohn's does not involve the colon beyond the rectum, or who have isolated small bowel disease, should not be offered surveillance and should join the general population screening program instead (East 2025). That is a statement about cancer surveillance only. It does not mean you will never need a scope for other reasons.

Risk has also been falling. The BSG 2019 guideline notes that earlier meta-analyzes found a 2 to 3% incidence by about 10 years after diagnosis, while later studies reported cumulative incidence of 1% at 10 years, 3% at 20 years and 7% at 30 years across inflammatory bowel disease, and suggests this may reflect surveillance, better inflammation control or colectomy (Lamb 2019). Those are IBD-wide figures, not Crohn's-specific ones.

When the first surveillance colonoscopy is due

If your Crohn's affects the colon, the first scope is suggested about 8 years after your symptoms started. The 2025 BSG guideline says people with IBD affecting the colon or rectum should be risk assessed for a surveillance program starting 8 years after the onset of symptoms, and that people with PSC-associated colitis should be offered participation from diagnosis (East 2025). The European guideline likewise says screening colonoscopy should be performed in all IBD patients 8 years after the onset of first symptoms, and that surveillance in adults with PSC should begin as soon as PSC is diagnosed (Gordon 2023). The 2019 BSG guideline gives the same figure and says to count from symptom onset where there was a significant delay before diagnosis (Lamb 2019).

Two practical details are easy to miss:

  • The 8 years run from symptoms, not diagnosis. Many people with Crohn's have years between first symptoms and a diagnosis. If yours were slow to be recognized, your first surveillance date may be earlier than you think.
  • The first scope is a baseline. In the BSG 2025 guideline, it is used to decide whether future surveillance is needed and how often. A baseline that shows low risk can mean you move to general population screening rather than a surveillance program (East 2025).

How often after that: the numbers, and why documents differ

This is where the headline figures people quote, 1, 3 and 5 years, come from, and where they have changed. Three documents are worth lining up.

BSG 2019, summarizing older 2010 guidance. Lower risk meant the next surveillance in 5 years, including Crohn's colitis affecting less than 50% of the colon. Intermediate risk meant 3 years, for example mildly active inflammation, post-inflammatory polyps or a first-degree relative with colorectal cancer aged 50 or over. Higher risk meant 1 year, for example moderate or severely active inflammation, a stricture or dysplasia in the last 5 years, PSC, or a first-degree relative with colorectal cancer under 50 (Lamb 2019). The authors flagged that the intervals were adapted from earlier guidance rather than freshly voted.

ECCO 2023. Statement 2.4 puts people with high-risk features, listed as a first-degree relative with colorectal cancer at 50 or younger, a colonic stricture or dysplasia, PSC, or extensive colitis with severe active inflammation, at a next colonoscopy in 1 year. Intermediate-risk features mean 2 to 3 years. Neither mean 5 years (Gordon 2023).

BSG 2025. The newest document changes the shape. It suggests annual surveillance for people who, after optimized medical therapy, still have moderate active inflammation, or dysplasia, PSC or a colonic stricture. It suggests surveillance every 3 years for mild persisting inflammation, post-inflammatory polyps, a first-degree relative with colorectal cancer, or extensive disease, which in Crohn's means more than 50% colonic involvement or inflammation in three or more colonic segments. For people with none of those risk factors it suggests reassessment every 10 years alongside age-appropriate population screening. It also suggests considering colectomy where severe inflammation persists despite optimized therapy (East 2025).

Risk groupBSG 2019 (adapted from 2010)ECCO 2023BSG 2025
Higher risk (stricture, dysplasia, PSC, severe or moderate activity)1 year1 yearAnnual
Intermediate (mild activity, post-inflammatory polyps, family history)3 years2 to 3 yearsEvery 3 years
Lower or no extra risk factors5 years5 years10-year reassessment

The 2025 BSG text explains the thinking behind the shift: previous guidance had suggested colonoscopic surveillance every 5 years for those at lower risk, but newer data suggest 3 years may be the appropriate minimum interval if surveillance is to effectively prevent colitis-associated cancer or cancer-related death (East 2025). The 2025 guideline also states that risk factors should be reviewed at clinic at least annually and the interval adjusted accordingly.

So if you have read that Crohn's colitis patients get a scope every 1, 3 or 5 years, that is a fair summary of the older framework. If your clinic has recently moved to a different pattern, it may well be following the 2025 guidance, or its own local protocol. Both can be reasonable. Ask which one is in use and why you sit in the group you do.

What the surveillance scope is like

Surveillance is best done when your Crohn's is in remission, because inflammation can make dysplasia hard to tell apart from active disease on biopsies. The European guideline says exactly that, and describes the use of dye-based or virtual chromoendoscopy with targeted biopsies to increase the yield of dysplasia detection (Gordon 2023). The BSG 2025 guideline suggests the procedure ideally be conducted in remission with pan-colonic dye spray (East 2025).

The preparation is the same ordeal as for any Crohn's colonoscopy, and a poor prep can mean a repeat. Our guide to colonoscopy prep tips with Crohn's covers the part that is different when you have strictures, previous surgery or perianal disease.

Stopping, and the age 75 conversation

The BSG 2025 guideline says that any decision to stop surveillance should be taken in partnership with the patient, weighing tolerance of and risks from colonoscopy and the practical implications of finding advanced neoplasia. It suggests a discussion at the age of 75 before continuing (East 2025). US guidance exists too: an AGA clinical practice update proposes a conceptual model and best-practice advice for preventing, detecting and managing dysplasia in IBD (Murthy 2021). We did not have access to its full text for this article, so we have not quoted its intervals. Ask your own team which guideline they follow.

Clock two: how often does treat-to-target need a colonoscopy?

Treat-to-target monitoring is the scope that checks whether a medicine has actually healed the lining, not just quietened the symptoms. The idea is simple: symptoms are an unreliable guide to inflammation, so progress is measured against targets, and treatment is reconsidered if they are not met.

What the targets are

The STRIDE-II consensus from the International Organization for the Study of IBD sets endoscopic healing as a long-term target for Crohn's and says to consider changing treatment if it has not been achieved. It says endoscopic healing can be assessed by sigmoidoscopy or colonoscopy, with capsule endoscopy or balloon enteroscopy as alternatives when that is not feasible, and defines it in Crohn's as an SES-CD score below 3 or absence of ulceration. It sets normalization of C-reactive protein and fecal calprotectin as intermediate targets, and treats transmural healing on imaging as an adjunct to endoscopic remission, not a formal target (Turner 2021).

How long after starting a drug?

Two documents help here. The ECCO-ESGAR diagnostic guideline says in Crohn's that clinical and biochemical response should be determined within 12 weeks, and endoscopic or transmural response should be evaluated within 6 months of starting therapy. It also says endoscopic or cross-sectional reassessment should be considered in relapse, persistent disease activity and before a switch of therapy (Maaser 2019).

STRIDE-II adds rough numbers by drug. They are expert estimates, not trial results, and the authors say plainly that the table should be considered a rough estimate given the scarcity of high-quality data. The mean number of weeks to reach endoscopic healing after starting treatment in Crohn's was estimated at:

TreatmentEstimated mean weeks to endoscopic healing
Oral steroids or exclusive enteral nutrition13
Budesonide15
Anti-TNF17
Ustekinumab19
Thiopurines24
Methotrexate24
Vedolizumab24

(Turner 2021.) Read them as a reason a clinic may wait a few months before scoping, not as a promise of how fast you personally will heal. They also explain why the common rule of thumb of a scope around 6 months after a change fits the evidence we could verify. We could not find a statement in the documents we opened that sets a universal 6 to 12 month schedule for treatment checks, so we have not claimed one.

Does the tight-control approach work?

The CALM trial compared two ways of managing 244 adults with early, moderate to severe Crohn's. In one, treatment was escalated according to symptoms alone. In the other, it was escalated using symptoms plus fecal calprotectin at or above 250 micrograms per gram and C-reactive protein at or above 5 mg/L. At week 48, 46% of the tight-control group reached mucosal healing with no deep ulcers, versus 30% in the clinical-management group (Colombel 2017). It is an open-label trial in people with relatively early disease, and long-term outcomes were left for later studies.

The relevance to scope timing is that biomarkers did a lot of the monitoring work in that strategy, with endoscopy used to define the outcome. In real clinics, calprotectin, blood tests, imaging and scopes are mixed, which is why your schedule can look different from a friend's.

The calendar version

ECCO-ESGAR also says the interval of monitoring should be between 3 and 6 months, depending on the duration of remission and current therapy (Maaser 2019). That statement is about ongoing monitoring generally, and in practice often means calprotectin and bloods, not a scope every 3 months. Nothing we read recommends a scope that frequently for someone who is well.

Clock three: when is a colonoscopy needed after ileocolic resection?

If you have had an ileocolic resection, a scope at around 6 to 12 months is the most standard timed colonoscopy in Crohn's, and it is the one with the best trial evidence behind it. For what to log in the months after bowel surgery, see food and symptom diary after a Crohn's bowel resection.

Why the first year matters

After surgery to remove the diseased ileum and join the bowel back up, Crohn's tends to come back first at the join. In a prospective cohort of 89 patients after ileal resection, endoscopic lesions in the new terminal ileum were seen within 1 year in 73% of patients, though only 20% had symptoms. At 3 years, endoscopic recurrence had risen to 85% and symptomatic recurrence was 34%. The severity of early lesions was the best predictor of the later course (Rutgeerts 1990). The same paper looked at 22 patients with a macroscopically normal new ileum at surgery, and 21 had ileitis at ileoscopy 6 months later.

That gap between what you feel and what the scope sees is the argument for looking at a set time, not waiting for symptoms.

How the Rutgeerts score works

The Rutgeerts score grades the new terminal ileum and the join. As reproduced in the BSG 2019 guideline, i0 means no lesions, i1 means up to 5 aphthous ulcers, i2 means more than 5 aphthous ulcers with normal intervening mucosa, or skip areas of larger lesions, or lesions confined to the ileocolonic anastomosis, and i3 is diffuse aphthous ileitis with diffusely inflamed mucosa. The scale runs up to i4 (Lamb 2019). Endoscopic recurrence is generally defined as i2 or above.

What the guidelines say about timing

The BSG 2019 guideline suggests, as a weak recommendation with low-quality evidence, that following ileocolonic resection an ileocolonoscopy may be performed at 6 months to assess the neoterminal ileum so that treatment escalation can be considered if there is mucosal inflammation of Rutgeerts i2 or above. If the join is out of reach, it suggests cross-sectional imaging with MR enterography instead (Lamb 2019). The ECCO-ESGAR guideline puts it as endoscopy within the first 6 to 12 months after surgery, where treatment decisions may be affected (Maaser 2019).

What the trial showed

The POCER trial randomized 174 patients across 17 centers in Australia and New Zealand. Everyone got 3 months of metronidazole, higher-risk patients also got a thiopurine or adalimumab, and then patients were assigned either to a colonoscopy at 6 months with step-up treatment if recurrence was found, or to standard care without one. At 18 months, endoscopic recurrence occurred in 49% of the active-care group versus 67% of standard care. In the active group, 39% stepped up treatment. The authors concluded that early remission does not preclude the need for ongoing monitoring, and that smoking and having two or more clinical risk factors increased the risk of recurrence (De Cruz 2015).

Note what this does and does not say. It supports a scope at 6 months as part of a strategy, in a trial where most patients were high risk. It does not tell you what happens after that first scope, and it does not tell your doctor which drug to choose. What comes next depends on your score and your risk factors.

Can anything replace a colonoscopy in Crohn's?

Scopes are not the only way to look at Crohn's, and in many clinics they are not the first step. The honest picture is that alternatives answer some questions well and others not at all.

Fecal calprotectin

Calprotectin is a stool test that tracks bowel inflammation. In a meta-analysis of 19 studies and 2,499 symptomatic IBD patients, pooled sensitivity for endoscopic activity was 0.88 and specificity 0.73, and fecal calprotectin was more sensitive in ulcerative colitis than in Crohn's (Mosli 2015). That matters because Crohn's in the small bowel can be missed by a stool marker more often than colitis. The BSG 2019 guideline calls it a validated biomarker for endoscopic and histological activity that may help decisions on treatment escalation or de-escalation (Lamb 2019).

After surgery, a meta-analysis of 9 studies found the best overall cut-off for detecting endoscopic recurrence was 150 micrograms per gram, with pooled sensitivity of 70% and specificity of 69% (Tham 2018). That is decent, not decisive, which is why it is used to decide who needs a scope soon rather than to replace the scope. Our post on a high calprotectin with no symptoms goes through what to do with a surprising number.

Intestinal ultrasound and MR enterography

A systematic review of 68 publications found ultrasound was accurate for assessing Crohn's activity, with sensitivity 0.84 and specificity 0.92, but less accurate for disease proximal to the terminal ileum. MRI had sensitivity 0.93 and specificity 0.90 for extent and activity and was less dependent on the operator. The review noted the absence of radiation as an advantage of ultrasound and MRI over CT (Panés 2011).

After surgery, a small retrospective study of 31 patients found ultrasound wall thickness correlated with the Rutgeerts score, with an area under the curve of 92.9% for wall thickness at a 3.4 mm cut-off. The authors called ultrasound a valid non-invasive alternative, and the sample size is a reason to read that cautiously (Yebra Carmona 2022). The BSG 2019 guideline says, in experienced hands, small bowel ultrasound is predictive of endoscopic findings with good correlation to the Rutgeerts score, and advises avoiding CT where possible to limit radiation (Lamb 2019).

STRIDE-II describes transmural healing as a measure of remission depth, not a formal target, and notes that discordance between endoscopic and transmural healing is not uncommon (Turner 2021). Our guide to intestinal ultrasound versus colonoscopy in Crohn's goes deeper on what each test can and cannot see.

Where alternatives fall short

For cancer surveillance, the guideline procedure is colonoscopy with dye spray or chromoendoscopy and biopsies. None of the documents we read presents calprotectin, ultrasound or MR enterography as a replacement for it. If you are offered an alternative in place of a surveillance scope, it is reasonable to ask whether your clinic is making an exception to the guideline and why.

TestGood atLimits
ColonoscopyDirect view of lining, biopsies, dysplasia surveillance, Rutgeerts and SES-CD scoringInvasive, needs preparation, may not reach all small bowel
Fecal calprotectinCheap, repeatable inflammation marker, can prompt a scopeLess sensitive in Crohn's than UC, not specific to where the inflammation is
Intestinal ultrasoundBowel wall thickness, activity, some complications, no radiationDepends on operator and local expertise, weaker above the terminal ileum
MR enterographyExtent and activity, small bowel, complications, no radiationAccess, time and contrast, does not take biopsies

Clock four: should symptoms or a relapse prompt a colonoscopy?

A scope can also be prompted by how you feel (to judge whether you are flaring first, see how to tell if you are in a Crohn's flare). The ECCO-ESGAR guideline says endoscopic or cross-sectional reassessment should be considered in relapse, in persistent disease activity and before switching therapy (Maaser 2019). Nothing in that is on a calendar.

The flip side is also true. Because symptoms and inflammation do not always match, feeling well does not remove the need for a scheduled scope, and feeling unwell does not always mean inflammation. The post-surgery data show it clearly: 73% with lesions, 20% with symptoms (Rutgeerts 1990).

When to see a doctor promptly

Do not wait for a scheduled scope if you notice any of the following. See a doctor promptly for:

  • Blood in your stool, or black or tarry stool.
  • Unexplained weight loss.
  • Fever with abdominal pain.
  • Symptoms that wake you at night.
  • New severe or persistent abdominal pain, repeated vomiting or a swollen abdomen, which can signal obstruction.
  • Signs of anemia, such as new breathlessness, pallor or marked tiredness.
  • A new or worsening perianal lump, pain or discharge.

Urgent severe pain, persistent vomiting or collapse needs emergency care. If you have a bowel cancer family history, tell your team, because it changes your risk group.

Three illustrations of different clocks

These are invented examples for illustration, not patients and not advice. They show why two people with Crohn's can sit very differently.

Someone with ileal-only Crohn's for 12 years. They have never had colonic involvement. Under the BSG 2025 suggestion for Crohn's not involving the colon beyond the rectum, they would not be offered cancer surveillance and would take part in general population screening. They may still have scopes, scans or a calprotectin check to monitor their ileal disease (East 2025).

Someone with Crohn's colitis for 9 years, symptoms first noticed 10 years ago. The surveillance clock started 8 years after symptoms, so they are due a risk-stratifying colonoscopy. Where it lands them depends on activity, extent, any strictures or polyps and family history. A person with more than 50% colonic involvement falls into the 3-yearly group in the 2025 BSG framework, and one with a stricture into the annual group (East 2025).

Someone who had an ileocolic resection 5 months ago. They are inside the typical 6 to 12 month window for a post-surgery ileocolonoscopy. The result, graded by the Rutgeerts score, shapes their next treatment step, and it is independent of the surveillance clock, which has not started or may be a separate one (Lamb 2019).

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

How do I work out my own colonoscopy schedule?

You do not need to memorize the guidelines. You need a handful of facts about yourself and a handful of questions. Gather these:

  1. The year your symptoms began, which may differ from your diagnosis year.
  2. Where Crohn's has been seen: ileum, colon, both, or anywhere else.
  3. Whether you have ever had a stricture, polyps or dysplasia, and when.
  4. Any bowel surgery, with the date.
  5. Whether you have PSC, and any family history of bowel cancer.
  6. The date and result of your last scope or scan.

Then ask your team:

  • Which of the four reasons is this scope for?
  • Which guideline or local protocol sets my interval?
  • If my calprotectin or scan is normal, does that change the date?
  • What would make the interval shorter or longer?
  • Is there a non-invasive test that could answer this particular question?

Our article on questions to ask your doctor about Crohn's has a longer list for the whole appointment.

If you keep records, Clairop can log symptoms, Bristol stool entries with blood, mucus, urgency and night-time detail, and medication, and produce a one-page GI visit report labeled as patient-entered data. It also calculates the Harvey-Bradshaw Index for Crohn's, with exam-only items left out and stated. It is free to download, using it needs a Clairop Pro subscription, it is iPhone only, and it is not a medical device, not clinically validated and not diagnostic. It will not tell you when a scope is due. What it can do is make the story between scopes easy to show. See how Clairop works and its method.

Myths about Crohn's and colonoscopy frequency

"Everyone with Crohn's needs a scope every year." No. Annual intervals in the 2025 BSG guideline apply to specific higher-risk situations such as persisting moderate inflammation, dysplasia, PSC or a colonic stricture. People without those risk factors may be moved to a 10-year reassessment (East 2025).

"Crohn's always means colon cancer screening from 8 years." Only if the colon is involved. Isolated small bowel Crohn's is not treated as a surveillance indication in the BSG guideline, and the European guideline notes the increased risk is present only in colonic involvement (Gordon 2023).

"If I feel fine, I can skip the scope." Not necessarily. Inflammation and symptoms can diverge, as the post-surgery data show, and cancer surveillance is meant to happen in remission (Rutgeerts 1990).

"A normal calprotectin means I do not need a surveillance colonoscopy." Calprotectin tracks inflammation. It does not screen for dysplasia, so it answers a different question (Mosli 2015).

"Ultrasound has replaced colonoscopy." For some monitoring questions it is used instead or alongside, but the guidelines we read keep colonoscopy for direct views, biopsies and surveillance (Panés 2011).

Limits of this article

We could not open the full text of the 2025 American College of Gastroenterology Crohn's guideline or the full AGA surveillance update, so we have not quoted their numbers. The 2019 and 2023 and 2025 documents differ in their intervals, and the older ones may still be what your clinic follows. Guidelines are not rules for an individual. This article is not medical advice and does not diagnose or replace your gastroenterologist, who knows your history. Do not start, stop or change any medication because of what you read here.

Frequently asked questions

How often do you need a colonoscopy with Crohn's disease?
It depends on why the scope is being done. Cancer surveillance is considered from about 8 years after symptoms begin if the colon is involved, then repeated every 1, 3 or 10 years by risk in the 2025 BSG guideline. Scopes to check a treatment, or after bowel surgery, are timed to those events rather than to a fixed calendar. Your gastroenterologist sets your schedule.
When should you start colon cancer screening with Crohn's?
Guidelines suggest a first colonoscopy about 8 years after symptoms began, counted from symptom onset rather than diagnosis, when Crohn's affects the colon. It is used to map disease extent and decide the next interval. People with primary sclerosing cholangitis start from diagnosis. Crohn's limited to the small bowel is not treated as a surveillance indication in the BSG guideline.
Do you need surveillance colonoscopies if Crohn's is only in the small intestine?
Usually not for cancer surveillance. The 2025 BSG guideline suggests that people with Crohn's not involving the colon beyond the rectum, or with isolated small bowel disease, should not be offered surveillance and should join general population bowel screening instead. You may still need scopes or scans for other reasons, such as checking treatment response.
How soon after bowel surgery do you need a colonoscopy for Crohn's?
Guidance suggests an ileocolonoscopy around 6 months after ileocolonic resection, and the ECCO-ESGAR diagnostics guideline recommends within the first 6 to 12 months. The aim is to look at the new join for early inflammation, graded with the Rutgeerts score, so treatment can be stepped up if needed. If the join cannot be reached, MR enterography may be used instead.
How soon after starting a new Crohn's treatment will I be scoped?
Often within about 6 months. The ECCO-ESGAR guideline says endoscopic or transmural response should be evaluated within 6 months of starting therapy, and STRIDE-II expert estimates put mean time to endoscopic healing between 13 and 24 weeks depending on the drug. Some clinics use calprotectin or ultrasound first. Ask your team which test they plan and why.
Can a calprotectin test replace a colonoscopy in Crohn's?
Not completely. Calprotectin is a useful marker of bowel inflammation, with pooled sensitivity of 0.88 and specificity of 0.73 for endoscopic activity across IBD studies, but it is less sensitive in Crohn's than ulcerative colitis. A raised value can prompt a scope, and a normal value is reassuring, but it cannot take biopsies or look for dysplasia.
Can intestinal ultrasound or MRI replace colonoscopy in Crohn's?
For some questions, yes. A systematic review found ultrasound was 84% sensitive and 92% specific for disease activity, and MRI 93% and 90%, with ultrasound weaker above the terminal ileum. They show the bowel wall and complications. Neither takes biopsies or screens the lining for dysplasia, so they are used alongside colonoscopy, not as a blanket substitute.
Is it normal to have no symptoms but still need a colonoscopy?
Yes. Symptoms and inflammation do not always match. In a classic post-surgery study, 73% of patients had lesions on ileoscopy within a year, but only 20% had symptoms. That is why scopes and biomarkers are used to check how the bowel looks. Cancer surveillance is also done in people who feel well, ideally while Crohn's is in remission.
What's the best way to prepare for a conversation about colonoscopy timing?
Use Clairop to keep a dated record of symptoms, Bristol stool entries and medication, then print its one-page GI visit report, which is labeled as patient-entered data. Add the year your symptoms began, where Crohn's affects you, any surgery, and your last scope date. Those facts, not the app, decide your interval. Clairop is not a medical device and does not diagnose.
What's the best test to monitor Crohn's without a colonoscopy?
No single test wins. Fecal calprotectin is a convenient first check on inflammation, intestinal ultrasound or MR enterography show the bowel wall and complications, and colonoscopy gives direct views and biopsies. Guidelines position them as complementary. The best choice depends on where your Crohn's sits, the question being asked and what your local service offers.

Sources

  1. East JE, Gordon M, Nigam GB, Sinopoulou V, Bateman AC, Din S, et al. British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease. Gut. 2025. doi:10.1136/gutjnl-2025-335023
  2. Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Al Sulais E, et al. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2023;17(6):827-54. doi:10.1093/ecco-jcc/jjac187
  3. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484
  4. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006;23(8):1097-104. doi:10.1111/j.1365-2036.2006.02854.x
  5. Murthy SK, Feuerstein JD, Nguyen GC, Velayos FS. AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. Gastroenterology. 2021;161(3):1043-51.e4. doi:10.1053/j.gastro.2021.05.063
  6. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-83. doi:10.1053/j.gastro.2020.12.031
  7. Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-64. doi:10.1093/ecco-jcc/jjy113
  8. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779-89. doi:10.1016/S0140-6736(17)32641-7
  9. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99(4):956-63. doi:10.1016/0016-5085(90)90613-6
  10. De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet. 2015;385(9976):1406-17. doi:10.1016/S0140-6736(14)61908-5
  11. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(6):802-19. doi:10.1038/ajg.2015.120
  12. Tham YS, Yung DE, Fay S, Yamamoto T, Ben-Horin S, Eliakim R, et al. Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn's disease: systematic review and meta-analysis. Therap Adv Gastroenterol. 2018;11:1756284818785571. doi:10.1177/1756284818785571
  13. Panés J, Bouzas R, Chaparro M, García-Sánchez V, Gisbert JP, Martínez de Guereñu B, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther. 2011;34(2):125-45. doi:10.1111/j.1365-2036.2011.04710.x
  14. Yebra Carmona J, Poza Cordón J, Suárez Ferrer C, Martín Arranz E, Martín Arranz MD, et al. Correlation between endoscopy and intestinal ultrasound for the evaluation of postoperative recurrence of Crohn's disease. Gastroenterol Hepatol. 2022;45(1):40-6. doi:10.1016/j.gastrohep.2021.02.010

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools